Myeloma
Millennium Initiates Phase III Trial to Determine the Optimal VELCADE (Bortezomib) for Injection Based Therapy in Newly Diagnosed Multiple Myeloma Patients
Published in Medicine and Law Weekly, August 3rd, 2007
Millennium Pharmaceuticals, Inc. (NASDAQ:MLNM) announced the initiation of a randomized, multi-center, Company-sponsored Phase III trial to determine the most effective VELCADE based combination therapy with approved agents for the treatment of newly diagnosed multiple myeloma (MM) patients, ineligible for stem cell transplantation. The trial, named UPFRONT and conducted primarily at community physician networks nationwide, will compare three VELCADE based therapies. VELCADE, currently the market leader in relapsed MM, is being developed for registration in front-line MM based on strong survival data seen in earlier clinical trials.
"VELCADE has delivered some of the...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medicine and Law Weekly
More Articles from Medicine and Law Weekly
- Anemia
Reports outline anemia in children research from Johns Hopkins University, Department of International Health - Chromatography
New findings from Hunan University in the area of chromatography published - Clinical Trial Research
Studies from Royal University have provided new information about clinical trial research in children - Criminology
Researchers from University of Oxford describe findings in criminology - Drug Abuse
Scientists at Taipei Medical University discuss research in drug abuse - Escherichia coli
Recent findings in escherichia coli described by L.S.S. Barros and colleagues - More from this issue of Medicine and Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
